Palvella Therapeutics, Inc. PVLA · Stock Open Palvella Therapeutics, Inc. in new tab
Analyst price targets
Recent rating changes, newest first
Palvella Therapeutics, Inc. Analysis (PVLA)
Is Palvella Therapeutics, Inc. a good investment? Palvella Therapeutics, Inc. (PVLA) is currently trading at 146.33 USD. Market analysts have a consensus price target of 228.40 USD. This suggests a potential upside from current levels.
Earnings Schedule: Palvella Therapeutics, Inc. is expected to release its next earnings report on Nov. 5, 2026. The market consensus estimate for Forward EPS is -7.91.
Investor FAQ
Does Palvella Therapeutics, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Palvella Therapeutics, Inc.?
Palvella Therapeutics, Inc. is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.
When is the next earnings date?
The next earnings date is projected to be Nov. 5, 2026. The company currently has a trailing EPS of -4.85.
Company Profile
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of angiokeratomas and other mTOR-driven skin diseases; and QTORIN pitavastatin for the treatment of disseminated superficial actinic porokeratosis. The company is based in Wayne, Pennsylvania.
| Split Date | Split Ratio to 1 |
|---|---|
| April 23, 2024 | 1:80 |
Community Discussion